FDA Regulatory Innovation

When Randomized Trials Are Not Possible: How Real-World Evidence Is Shaping FDA Drug Approvals

The U.S. Food and Drug Administration’s recent approval of leucovorin (Wellcovorin) for cerebral folate transport deficiency caused by FOLR1 gene variants highlights an increasingly important trend in regulatory science: the growing role of real-world evidence in drug approval decisions.

For many therapies, especially those targeting common diseases, randomized controlled trials remain the gold standard for demonstrating safety and effectiveness. But for ultra-rare conditions, traditional clinical trials may be difficult, and sometimes impossible, to conduct. The FDA’s approval of leucovorin illustrates how regulators are adapting their evidentiary framework when conventional trial designs are not feasible.

The Challenge of Ultra-Rare Diseases

Cerebral folate transport deficiency due to FOLR1 variants is an extremely rare genetic disorder affecting the brain’s ability to transport folate, a vitamin critical for neurological development and function. Patients often experience severe neurological complications, including developmental delays, seizures, movement disorders, and autistic features.

Because the condition affects only a small number of individuals worldwide, assembling a large randomized clinical trial population would be impractical. In such situations, regulators must determine whether other forms of scientific evidence can sufficiently demonstrate clinical benefit.

Evidence Beyond Traditional Trials

In approving leucovorin for this indication, the FDA relied on a systematic review of the scientific literature, including published case reports with patient-level clinical information, mechanistic studies explaining the biological role of folate transport, and observational evidence showing patient improvement compared with the natural progression of the disease.

This approach reflects a broader regulatory concept known as the “totality of evidence”, in which multiple sources of scientific information collectively support a regulatory decision. Rather than relying solely on large clinical trials, regulators evaluate how well the available evidence explains the biological plausibility, clinical outcomes, and risk-benefit profile of the therapy.

The Growing Role of Real-World Evidence

Real-world evidence (RWE) refers to clinical information derived from sources outside traditional randomized trials, such as observational studies, patient registries, published case reports, and real-world clinical practice data. In recent years, FDA has increasingly explored how RWE can complement traditional clinical data, particularly in situations where randomized trials are not practical.

For rare diseases, RWE can help regulators understand how patients respond to treatments in real clinical settings and how outcomes compare with the natural history of the disease.

Regulatory Flexibility Without Lowering Standards

Importantly, the use of real-world evidence does not mean that regulatory standards are lowered. Instead, it reflects an effort to apply scientific judgment to the realities of rare disease research. FDA officials emphasized that the approval still required convincing evidence that the treatment provides meaningful clinical benefit.

In the case of leucovorin, the therapy’s biological mechanism and clinical observations together supported the conclusion that patients with FOLR1-related cerebral folate deficiency could benefit from treatment.

A Model for Future Rare Disease Approvals

The approval of leucovorin for CFD-FOLR1 may serve as an example of how regulatory science is evolving to address rare conditions. As genomic medicine continues to identify increasingly specific disease subtypes, regulators will likely face more situations where traditional large clinical trials are impractical.

In these cases, approvals may increasingly rely on strong mechanistic understanding, observational clinical data, natural history comparisons, and real-world evidence.

The Bottom Line

The FDA’s decision to approve leucovorin for cerebral folate transport deficiency underscores a key shift in regulatory thinking. When rigorous randomized trials are not feasible, regulators may rely on a broader scientific evidence framework to evaluate therapies for rare diseases. And for patients with ultra-rare conditions, this approach can accelerate access to potentially life-changing treatments while maintaining the scientific standards necessary to ensure safety and effectiveness.

As biomedical science continues to uncover rare genetic disorders, regulatory frameworks that integrate real-world evidence, mechanistic data, and clinical observation will likely play an increasingly important role in bringing new therapies to patients who previously had no treatment options.